Undisclosed Target Program
Oncology
DiscoveryActive
Key Facts
About Apertor Pharmaceuticals
Apertor Pharmaceuticals is a private, preclinical-stage biotech pioneering a novel approach to disrupt protein-protein interactions (PPIs) in oncology. Its core technology platform develops 'Interceptors,' heterobifunctional small molecules that recruit the abundant intracellular protein FKBP12 to sterically obstruct oncogenic signaling complexes, offering a differentiated mechanism from protein degraders like PROTACs. The company is advancing a pipeline led by a program targeting mTORC1/4E-BP1 in solid tumors and is backed by a team of experienced founders and scientific advisors with deep expertise in chemical biology and drug discovery.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |